Abstract 1339
Background
Esophageal squamous cell carcinoma (ESCC), a common gastrointestinal tumor, is listed as the sixth leading cause of cancer-related death worldwide, with high morbidity and mortality as its important characteristics. In recent years, despite advances in diagnosis and treatment of ESCC, the mortality rate of ESCC is still very high, with an average overall 5-year survival rate of about 10% ∼ 41%.As with many other solid tumors, development and progression of ESCC are also considered gene regulatory disorders caused by oncogene activation and inactivation accumulation and disorders of tumor suppressor genes (TSG). Therefore, screening and exploring the key gene proteins for the occurrence, development, treatment and clinical prognosis of ESCC is an important topic in the field of ESCC research at present.
Methods
Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining were employed to determine IBSP expression at the mRNA and protein levels in clinical ESCC samples. Moreover, functional studies were adopted to study the tumor-promoter function of IBSP.
Results
IBSP up-regulation was found in 21 of 45 (46.7%) primary ESCC cells at mRNA level by transcription-polymerase chain reaction (RT-PCR). In addition, IHC staining further demonstrated that IBSP was up-regulated in ESCC cases and up-regulation of IBSP protein was significantly relevant to lymph node metastasis (P = 0.017), clinicopathologic stage (P = 0.001) and poor disease survival (P = 0.000) of ESCC patients. Moreover, functional studies illustrated that IBSP gene can promote the ability of proliferation and metastasis of ESCC cells. Furthermore, it was found that IBSP can regulate the EMT process by regulating MMP2 gene and N-cadherin, which promotes the metastasis of tumor cells.
Conclusions
the results of this study showed that IBSP up-regulation was often found in ESCC tumor specimens, indicating poor prognosis of ESCC patients. Moreover, it also demonstrated that IBSP could improve the ability of ESCC cell proliferation and tumor metastasis, which may be a valuable prognostic indicator in ESCC patients. Yet, the mechanism by which IBSP promotes tumorigenesis and development needs more researches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract